New [Premium Alert] PluriTM Receives "First-Ever Patent Approval" for 3D Bioreactor Technology

NASDAQ: PLUR - Can this sky-rocket? First Ever Patent Approval New Premium Alert For 3/21 Trading Session Red Hot Biotech Receives First Ever Patent Approval Pluri Inc. NASDAQ: PLUR [ See Company Presentation Here ]( Hi 10XProTrader member, This is Kevin Vander with "10XProTrader" delivering you your new premium alert for Thursdays 3/21 trading session Pluri Inc. [NASDAQ: PLUR]. This leading biotechnology company Pluri Inc. recently caught my attention, and I'm positive as your scroll through my special report below you'll be convinced as well that this company is a total game-changer! The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel. I encourage you to take a look at the PLUR company presentation. [See It Here]( Catalyst #1 For Sky-Rocketing Share Potential PLUR Triggers a Short & Medium Term STRONG BUY! [Click Here To See Proof]( Do you see what I see? You can NOT get a better looking bullish chart than this with PLUR. The stock has DOUBLED in price in 60 days. If the momentum and news stays consistent, this stock has the potential to sky rocket from here and potentially see $2.00. There are multiple catalysts developing right now that could potentially send shares of PLUR breaking out. Huge Breakout Setup For PLUR PLUR is displaying what some consider the Holy grail of Bullish signals - a Golden Cross. Look at the chart below, you will see the 50 day MA (red line) moves up through the 200 day MA) (blue line). Strong Buy 88% Both Short & Medium [Click Here To See Proof]( See the technical indicators on PLUR is right now below. The timing for you could be incredible, and at the same time you may never see this again. I would hate to see you miss out on this. I urge you to confirm my research now. Below is The Short Term Indicators 20 Day Moving Average = BUY 20 - 50 Day MACD Oscillator = BUY 20 - 100 Day MACD Oscillator = BUY 20 -200 Day MACD Oscillator = BUY Below is The Medium Term Indicators 20 Day Moving Average = BUY 20 - 50 Day MACD Oscillator = BUY 20 - 100 Day MACD Oscillator = BUY 20 -200 Day MACD Oscillator = BUY Catalyst #2 For Sky-Rocketing Share Potential Pluri, Inc. Pushing The Boundaries Worldwide Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food-tech and agtech and aims to establish partnerships that leverage the Company’s 3D cell-based technology to additional industries that require effective, mass cell production. Catalyst #3 For Sky-Rocketing Share Potential The Global Cellular Agriculture Market Was Valued at $133 Bln in 2021 and is Projected To Hit $515 Bln by 2030! Growth Trajectory Enormous Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation Patent helps position Pluri as a leader in cell expansion for the agtech industry with the launch of its PluriAgtech business vertical and cell-based coffee product HAIFA, Israel – March 11, 2024 – In a strategic move that underscores its innovative edge in the agtech sector, Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company") today announced an important expansion to its intellectual property portfolio with a new patent approval, that is designed to reshape the agricultural technology landscape. The patent titled “A System for 3D Cultivation of Plant Cells and Methods of Use” represents a major breakthrough in Pluri's proprietary 3D bioreactor technology, enabling efficient cultivation of plant cells across various applications, from sustainable agriculture to critical healthcare solutions. An immediate application for the patent is PluriAgtech’s sustainable cell-based coffee. The 3D cell expansion technology can produce high-quality coffee with 98% less water and 95% less growing area. Pluri’s patent and 3D cell expansion technology can also potentially address an emerging gap in agricultural healthcare, as approximately one-fifth of the 50,000 medical plants used today are on a list of threatened species. Catalyst #4 For Sky-Rocketing Share Potential Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals - Growing pipeline of industry-specific new potential products, services, collaborations and partnerships through PluriAgtech, PluriCDMO, PluriHealth, and PluriFood - Recent achievements include: new cell-based coffee business; new agtech division and first partners; new Contract Development and Manufacturing Organization division; $4.2 million Contract with the U.S. NIH and new partnership with Bar-Ilan University - Landmark collaboration with Tnuva Group continues to drive its technology forward with interest from global partners Dear Fellow Shareholders, As we move into 2024, I’m proud to share my thoughts about all the exciting things happening at Pluri right now. As a purpose-driven company with goal-oriented leadership and a deep commitment to our shareholders, we enter 2024 with significant momentum in every area of our business, validating our approach and demonstrating strong execution. Over the past several months, we’ve launched PluriAgtech, a new business vertical focused on applying our cell-based technologies to improve agriculture; and PluriCDMO, a contract development and manufacturing organization (CDMO) division,with the goal to drive revenues and cash flow while continuing to advance healthcare therapeutics. We are building long-term strategic alliances and partnerships with companies that are leaders in their respective fields, have market access, employ a similar approach to innovation, and are committed to pioneering a biotech revolution with us, with the goal to accelerate time to market. Despite the myriad of challenges associated with scaling a business during these difficult times, the last few months have been especially exciting for Pluri, bringing significant progress in multiple areas. Just as Israel has demonstrated resilience, Pluri has also demonstrated immense strength over the last few months, showing our partners and customers that we deliver innovation no matter what the current circumstances are. In fact, we’re coming off a year of successes that offer a glimpse of the bright future ahead for Pluri: Catalyst #5 For Sky-Rocketing Share Potential PluriAgtech’s Innovative Answer To The Global Coffee Crisis: Sustainable Cell-Based Coffee In January 2024, we launched our cell-based coffee business, pioneering a new and game-changing way to address the rapidly growing $130 bln coffee industry in a more sustainable, eco-friendly way. The coffee industry is currently at risk as global warming is expected to slash the amount of land available for coffee production by up to 50% by 2050. Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production. We also estimate that our innovative new production process will reduce the amount of growing area by 95%, potentially preventing deforestation. Catalyst #6 For Sky-Rocketing Share Potential PluriCDMO to Support Development of Life-Changing Cell and Gene Therapies for Biotech Companies, and Potentially Generate Revenues and Ca∙sh Flow for Pluri In January 2024, we launched our CDMO division, to provide services to innovative biotech companies in the rapidly growing $5.2 Bln cell and gene therapy sector. PluriCDMO includes not only our experienced clinical and bio-manufacturing team but also our robust Good Manufacturing Practice (GMP) facility and our proprietary 3D cell-expansion technology. We believe PluriCDMO can be the launchpad so many companies need to take their cell and gene therapies to the next level. Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production. We also estimate that our innovative new production process will reduce the amount of growing area by 95%, potentially preventing deforestation. While we already started generating revenues from this division, we are receiving a lot of additional interest and are currently negotiating several CDMO agreements. PluriCDMO  provides substantial value to our clients by offering; access to extensive knowledge, mass scale production oppor∙tunities and expedited time to market. We expect this division to boost Pluri’s revenues and cash flow through the utilization of our well-established technology and GMP-certified facility. Catalyst #7 For Sky-Rocketing Share Potential PluriHealth & U.S. NIH Advance Development of PLX-R18 as Countermeasure for H-ARS Russia’s invasion of Ukraine and Vladmir Putin’s dangerous rhetoric have raised the specter of nuclear war, and the global medical community must prepare for the worst-case scenario. Unfortunately, the world remains unprepared for a nuclear attack or a major accident. Medical responses to nuclear radiation poisoning have failed to keep pace, while nuclear weaponry has grown exponentially more powerful since World War II. In July 2023, we signed a 3-year, [$4.2 Mln. contract]( with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to advance the development of our PLX-R18 cell therapy as a potential novel treatment for Hema∙topoietic Acute Radi∙ation Syndrome (H-ARS). We are collaborating with the U.S. Department of Defense’s (DoD) Armed Forces Radiobiology Research Institute (AFRRI)/Uniformed Services University of Health Sciences (USUHS) in Maryland. PLX-R18 is being developed with the intention of being eligible for purc∙hase by the U.S. Strategic National Stockpile as a medical countermeasure for exposure to nuc∙lear rad∙iation, following U.S. Food and Dr∙ug Administration (FDA) approval. Catalyst #8 For Sky-Rocketing Share Potential Collaboration with Bar-Ilan University Develops PLX Cells to Treat Coc∙aine Addiction Another example of executing our partnered-based strategy is the agreement we signed with BIRAD, the commercial division of Bar-Ilan University. BIRAD – Research & Development Company has the right to further develop and commercialize PLX cells as a product to treat coc∙aine addiction and Pluri is entitled to a 20% revenue share from future sales of the product. The lack of any FDA-approved medications to treat coc∙aine addiction presents a significant oppor∙tunity in a critical health area with significant unmet need. We expect that additional partnership agreements will continue to drive our current PluriHealth pipeline to commercialization. Catalyst #9 For Sky-Rocketing Share Potential Ever After Foods’ Promising Development Within one year of its establishment, [E]( After Foods]( announced a 700% increase in productivity compared to other cultivated meat companies, showing the great promise of our technology when it comes to scale and cost parity. Ever After Foods’ long-term goal is to serve as a technology enabler for the broader industry. Ever After Foods is led by a stellar management and operational team and we expect to share some exciting developments over the coming months. Catalyst #10 For Sky-Rocketing Share Potential Transforming The World Through Cell-Based Technology, Building High Value Companies, Near-Term Revenues and Ca∙sh Flow We believe our technology is pivotal for solving some of the most important trials facing humanity today. As a global leader in cell-based technology, Pluri is setting the stage for a future full of hope in the areas of food security, climate change, sustainability, health and aging. [Click here to see the 1 - 10 catalyst for explosive share growth]( Conclusion: Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The stock has triggered BOTH the Short & Medium term indicators to a BUY signal. The chart is extremely bullish. Take Action: Put (PLUR) at the top of your watchlist for Thursday morning... Im urging all of our "10X" members to add Pluri, Inc. (NASDAQ: PLUR) to the top of your watch list right now! Yours for greater gains, Kevin Vander Publisher, 10XProTrader.com Investment Research You are receiving this e-mail as part of your subscription to 10XProTrader. Please do not reply to this e-mail as this address is not monitored. Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2023 10XProTrader.com. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular inves∙tment situation. N∙o communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers, prior or during our reporting on the company. © 2024 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inve∙stment for any specific individual. This communication is a paid a∙dvertisement. 10XProTrader.com and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $20,000 USD to disseminate this communication. Please note that we do not trade any securities that we profile. We do not hold positions in stocks we profile. We do not except stock as a form of payment for our profiles. Please review the full disc∙laimer at [( for important information about this advertisement. © 2023 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.